In joint news releases, both the Foudation Fighting Blindness (FFB) and Oxford BioMedica announced that FFB had recently awarded $125,000 to the Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, a clinical trial site for UshStat, a gene therapy developed by Oxford BioMedica for people with Usher syndrome type 1B (USH1B). The funding level is the amount needed for the site, located in Paris, France, to take part in the study.
Usher syndrome is the world's leading cause of combined blindness and deafness. The condition affects approximately 45,000 people in the United States. USH1B is a form of the disease caused by (Read more...)